Schrödinger has entered a strategic agreement with Bristol Myers Squibb (BMS) to integrate its AI-based co-scientist platform Bunsen into BMS’s research operations. This initiative builds on an established partnership between the two companies, under which BMS already utilises Schrödinger’s computational platform for drug discovery projects. Schrödinger platform chief scientific officer Robert Abel said: “BMS is a long-standing customer and collaborator, and they have been an industry leader in integrating computation into drug discovery. Adopting Bunsen and our computational platform at scale will empower a broader group of scientists to embrace a predict-first computational approach.” Schrödinger reports that its software platform combines AI with physics-based simulation to support hypothesis evaluation and synthetic feasibility in molecular research.